Lokavant
The business, the turning points, and the decisions behind them.
Some sections are still being researched2 / 4
Sections to complete：02 · 05
01 / WHAT IT BUILT
What the company did
Lokavant (spun out of Roivant Sciences in 2020, led by Rohit Nambisan) built clinical trial intelligence technology: machine-learning models that meld historical and real-time trial data to anticipate trial risk, provide risk mitigation strategies, and predict the impact of mitigation. Its platform aggregates real-time data from disparate trial data sources, compares them against a compendium of 1,000+ historical trials to flag issues early, and gives sponsors and CROs real-time visualizations and risk alerts for data-driven decisions — with the stated mission that no clinical trial should fail due to operational error.
02 / FAILURE REASONS
Material for this section is being gathered and checked. It will appear here once ready.
03 / EVENT HISTORY
Events in the structured record
- Launched
Launched as a Roivant Sciences subsidiary ('Vant') with the mission of ensuring no clinical trial fails due to operational error.
- Funding
Edison Partners led a $21 million funding round; Mitsui & Co. separately invested $8 million to expand Lokavant in Japan and Asia.
- Acquired by ProofPilot
On September 20, 2025, ProofPilot (an end-to-end clinical experience platform) announced it was acquiring Lokavant, merging ProofPilot's trial execution capabilities with Lokavant's predictive analytics to create a combined platform for sponsors and CROs.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN / AFTERMATH
Material for this section is being gathered and checked. It will appear here once ready.